Evaluation of Clinical Value and Potential Mechanism of MTFR2 in Lung Adenocarcinoma via Bioinformatics

Abstract

Background: Mitochondrial fission regulator 2 (MTFR2) was involved in the progression and development of various cancers. However, the relationship between MTFR2 with lung adenocarcinoma (LUAD) had not been reported. Herein, this study analyzed the clinical significance and potential mechanisms of MTFR2 in LUAD via bioinformatics tools.Results: We found that the level of MTFR2 was increased, and correlated with sex, age, smoking history, neoplasm staging, histological subtype and TP53 mutation status in LUAD patients. Kaplan-Meier survival analysis showed LUAD patients with increased MTFR2 had a poor prognosis. In addition, univariate COX regression analysis showed neoplasm staging, T stage, distant metastasis and MTFR2 level were risk factors for the prognosis of LUAD. A total of 1127 genes were coexpressed with MTFR2, including 840 positive and 208 negative related genes. KEGG and GSEA found that MTFR2 participated in the progression of LUAD by affecting cell cycle, DNA replication, homologous recombination, p53 signaling pathway and other mechanisms. The top 10 coexpressed genes, namely CDK1, CDC20, CCNB1, PLK1, CCNA2, AURKB, CCNB2, BUB1B, MAD2L1 and BUB1 were highly expressed, and were associated with poor prognosis in LUAD. Conclusions: Consequently, we elucidated MTFR2 was a biomarker for diagnosis and poor prognosis in LUAD, and might participate in the progression of LUAD via affecting cell cycle, DNA replication, homologous recombination and p53 signaling pathway.

Association of High Expression of Mitochondrial Fission Regulator 2 with Poor Survival of Patients with Esophageal Squamous Cell Carcinoma

“…Its altered expression affected the proliferation and metastasis of breast cancer and inhibited epithelial mesenchymal transition. Other similar studies found that the high expression of MTFR2 was related to the clinicopathology, diagnosis and prognosis, and promot-ed the occurrence and cancer development through p53-dependent cell cycle, DNA replication, and homologous recombination in lung cancer [13]. Such findings may highlight the potential role of MTFR2 in ESCC as a novel therapeutic target for treatment.…”

“…Some previous studies found that the high expression of [11,12]. Currently, some studies have shown that MTFR2 is overexpressed in glioblastoma (GBM) and lung cancer, and this was correlated with sex, age, smoking history, cancer stage, histological subtype, and TP53 mutation status of lung cancer [9,13]. However, the role of MTFR2 expression in ESCC remains unclear.…”

Identification of Potential Key Genes and Prognostic Biomarkers of Lung Cancer Based on Bioinformatics

“…Overexpression of CDK1 in lung cancer reduces chemosensitivity and is related to the lower survival rate of patients [33][34][35]. According to the literature, direct inhibition of CDK kinase activity is the basic strategy for developing effective cell cycle inhibitors [36]. Based on the results of this study, we speculate that CDK1 has excellent value in the survival and prognosis of lung cancer patients and may provide some possibilities for targeted drug delivery of lung cancer chemotherapy.…”